Avalon Investment & Advisory’s PRA Health Sciences, Inc. PRAH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-42,860
| Closed | -$7.08M | – | 377 |
|
|
2021
Q2 | $7.08M | Buy |
42,860
+1,363
| +3% | +$228K | 0.16% | 124 |
|
|
2021
Q1 | $6.36M | Buy |
41,497
+3,877
| +10% | +$527K | 0.15% | 118 |
|
|
2020
Q4 | $4.72M | Sell |
37,620
-989
| -3% | -$111K | 0.1% | 136 |
|
|
2020
Q3 | $3.92M | Sell |
38,609
-5,158
| -12% | -$526K | 0.09% | 137 |
|
|
2020
Q2 | $4.26M | Sell |
43,767
-12,940
| -23% | -$1.2M | 0.1% | 136 |
|
|
2020
Q1 | $4.71M | Sell |
56,707
-4,178
| -7% | -$407K | 0.12% | 141 |
|
|
2019
Q4 | $6.77M | Buy |
60,885
+692
| +1% | +$71.2K | 0.14% | 134 |
|
|
2019
Q3 | $5.97M | Sell |
60,193
-780
| -1% | -$77.5K | 0.13% | 135 |
|
|
2019
Q2 | $6.04M | Buy |
60,973
+27,942
| +85% | +$2.67M | 0.13% | 139 |
|
|
2019
Q1 | $3.64M | Sell |
33,031
-19,187
| -37% | -$2.01M | 0.08% | 161 |
|
|
2018
Q4 | $4.8M | Buy |
52,218
+2,572
| +5% | +$260K | 0.12% | 143 |
|
|
2018
Q3 | $5.47M | Buy |
49,646
+3,489
| +8% | +$363K | 0.15% | 157 |
|
|
2018
Q2 | $4.31M | Buy |
46,157
+21,893
| +90% | +$1.89M | 0.13% | 157 |
|
|
2018
Q1 | $2.01M | Buy |
24,264
+2,199
| +10% | +$195K | 0.06% | 213 |
|
|
2017
Q4 | $2.01M | Buy |
22,065
+1,106
| +5% | +$92K | 0.06% | 202 |
|
|
2017
Q3 | $1.6M | Sell |
20,959
-134
| -0.6% | -$10.1K | 0.05% | 201 |
|
|
2017
Q2 | $1.58M | Buy |
21,093
+2,695
| +15% | +$187K | 0.05% | 203 |
|
|
2017
Q1 | $1.2M | Buy |
+18,398
| New | +$1.08M | 0.04% | 235 |
|
Other funds holding PRAH
Avalon Investment & Advisory's PRAH Position: Q3 2021 in Review
Avalon Investment & Advisory sold out of PRA Health Sciences, Inc. (PRAH) in Q3 2021, closing a stake of 42,860 shares — an estimated $7.08M sold.
Avalon Investment & Advisory first reported a position in PRAH in Q1 2017 and held it in 18 quarters. The position peaked at $7.08M in Q2 2021. 1 fund tracked by Wall St. Rank holds PRAH as of Q3 2021.
- Avalon Investment & Advisory reported no remaining PRA Health Sciences, Inc. position as of Q3 2021 after selling out during the quarter.
- Avalon Investment & Advisory sold 42,860 PRA Health Sciences, Inc. shares in Q3 2021, an estimated $7.08M.
- Avalon Investment & Advisory first reported a position in PRA Health Sciences, Inc. in Q1 2017 and held it in 18 quarters.
- Avalon Investment & Advisory's PRA Health Sciences, Inc. position peaked at $7.08M in Q2 2021.
- 1 fund tracked by Wall St. Rank held PRA Health Sciences, Inc. as of Q3 2021.
Based on Avalon Investment & Advisory's 13F filing for Q3 2021, filed 8 Nov 2021.